* Zymeworks Inc is expected to show a fall in quarterly revenue when it reports results on October 31 for the period ending September 30 2024
* The Middletown Delaware-based company is expected to report a 7.3% decrease in revenue to $15.303 million from $16.51 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.
* LSEG's mean analyst estimate for Zymeworks Inc is for a loss of 40 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Zymeworks Inc is 14.00, above its last closing price of $13.24.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.32 -0.27 Beat 14.7
Mar. 31 2024 -0.29 -0.42 Missed -44.8
Dec. 31 2023 -0.46 -0.43 -0.20 Beat 53.9
Jan. 1 0001 -0.50 -0.47 -0.41 Beat 12.7
Jun. -0.49 -0.47 -0.76 Missed -61.6
30 2023
Jan. 1 0001 -0.55 -0.54 -0.36 Beat 32.9
Dec. 31 2022 4.44 4.84 4.65 Missed -3.9
Jan. 1 0001 -0.91 -0.92 -0.72 Beat 21.8
This summary was machine generated October 29 at 21:05 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。